findmyKOL

Marwan Fakih, MD

Enriched profile

Deputy Director, Comprehensive Cancer Center, City of Hope · City of Hope Comprehensive Cancer Center

ORCIDNPI
Region🇺🇸 Duarte, CA · West · United StatesSpecialtyMedical OncologyFocusColorectal Cancer Treatments and Studies+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2022–2026

Marwan Fakih is Deputy Director, Comprehensive Cancer Center, City of Hope at City of Hope Comprehensive Cancer Center. OpenAlex indexes 704 publications with 27,938 citations (h-index 72); ClinicalTrials.gov lists 27 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Marwan G. Fakih, MD, is Deputy Director, Comprehensive Cancer Center, City of Hope at City of Hope Comprehensive Cancer Center. The public record shows 704 publications with 27,938 citations (h-index 72), centered on Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations. It also documents an investigator role on 27 registered clinical trials, industry payments reported by 29 companies, 1 NIH-funded awards (2022–2026).

  • Most recent indexed publication: 2026 · JCO precision oncology
  • Top research focus: Colorectal Cancer Treatments and Studies
  • 27 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 29 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Colorectal Cancer23 trialsRectal Neoplasms22 trialsColonic Neoplasms8 trialsDiarrhea1 trialGastroesophageal Cancer1 trialCarcinoma, Squamous Cell1 trialEsophageal Squamous Cell Carcinoma1 trialSarcoma1 trialSarcoma, Ewing1 trialComa1 trialLung Cancer (NSCLC/SCLC)

Research focus

OpenAlex concept fingerprint
Colorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsGenetic factors in colorectal cancerCancer Genomics and Diagnostics

Drugs & molecules

across trials, industry payments and publications
Onivydegeneric · IrinotecanClinical trials1Industry payments1Publications1Lonsurfgeneric · Tipiracil / trifluridineClinical trials1Industry payments9PublicationsStivargageneric · RegorafenibClinical trialsIndustry payments6Publications2

Works with

trial sponsors and companies reporting payments
Taiho Oncology, Inc.Clinical trialsIndustry payments21Abbvie Inc.Clinical trialsIndustry payments14City of Hope Medical CenterClinical trials13Industry payments

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
704publications

Distinct works indexed by OpenAlex, matched via ORCID; 27 in PubMed.

27,938citations

Total citations across indexed works.

72h-index

Hirsch index (OpenAlex). i10-index 267.

Clinical & industry

trials, payments and federal funding
27clinical trials

Investigator role on registered studies.

View trials
29companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2022–2026

Federally funded research awards.

View funding

Industry payments

Updated 27 Aug 2026

29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    28.9%
    Serotonin-3 Receptor Antagonist21.1%
    Ondansetron Hcl100%
    Part D18 patients
    Bile Acid7.8%
    Ursodiol100%
    Part D<11 patients
  • Cancer & immunology

    25.3%
    Nucleoside Analog Antiviral25.3%
    Lonsurf100%
    Part D<11 patients
  • Sensory organs

    21.1%
    Corticosteroid21.1%
    Dexamethasone100%
    Part D18 patients
3 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)95.6% facility · 4.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

1 NIH research award on record, funded 20222026 per NIH RePORTER. The latest:

Congress activity

Updated 27 Aug 2026

228 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/marwan-fakih-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/marwan-fakih-29089ab

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • LinkedIn

    linkedin.com/in/marwan-fakih

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
2 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • X / Twitter

    x.com/montypal/status/1964405443218067494

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Fellowship

    Hematology and Oncology, University of Pittsburgh

    2001
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org
  • Residency

    Internal Medicine, Detroit Medical Center/Wayne State University

    1995
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org
  • M.D.

    American University of Beirut

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org
  • Board Certified

    Internal Medicine (American Board of Internal Medicine)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com
  • Board Certified

    Medical Oncology (American Board of Internal Medicine)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com

Editorial & leadership roles

journal and society appointments
3 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
3 more affiliations behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.